--- title: "Adjuvant Non Small Lung Cancer TroFuse-019 | Sutter Health" description: "A Phase 3 Randomized Open-Label Study of Adjuvant Pembrolizumab With or Without MK-2870 in Participants With Resectable Stage II to IIIB (N2) NSCLC Not Achieving pCR After Receiving Neoadjuvant Pembrolizumab With Platinum-based Doublet Chemotherapy Followed by Surgery (MK-2870-019) (TroFuse-019)" url: "https://www.sutterhealth.org/research/clinical-trials/adjuvant-non-small-lung-cancer-trofuse-019-2015848648" --- 1. [Home](https://www.sutterhealth.org/) / 2. [Research](https://www.sutterhealth.org/research) / 3. [Clinical trials](https://www.sutterhealth.org/research/clinical-trials) / 4. Adjuvant Non Small Lung Cancer TroFuse-019 # Adjuvant Non Small Lung Cancer TroFuse-019 **Status:** Open to Enrollment [Email us to enroll](https://www.sutterhealth.org/research/clinical-trials/adjuvant-non-small-lung-cancer-trofuse-019-2015848648#enroll) #### Study details View study details on [www.clinicaltrials.gov](https://www.clinicaltrials.gov/study/NCT06312137). #### Locations - San Francisco #### Clinical trial FAQs Information for patients and study volunteers, including [frequently asked questions](https://www.sutterhealth.org/research/faqs). This study will assess if adding sacituzumab tirumotecan with pembrolizumab after surgery is effective in treating NSCLC for participants not achieving pathological complete response. The primary hypothesis of this study is sacituzumab tirumotecan plus pembrolizumab is superior to pembrolizumab monotherapy with respect to disease free survival (DFS) as assessed by blinded independent central review (BICR). ![Alan M Kramer, M.D.](https://dyn.mktgcdn.com/p/O2mfW45nC3I_WEoGQs3tLcwYJmLfdRPAt2DnngSU74w/fit=crop,gravity=auto,dpr=2,width=188,height=250,quality=100) Alan M Kramer, M.D. Principal investigator [View profile](https://www.sutterhealth.org/research/investigators/alan-m-kramer-md-1049681189) ## Sub-Investigator [Kevin B Kim, M.D.](https://www.sutterhealth.org/research/investigators/kevin-b-kim-md-1049681162) ## Email us to enroll - [Email San Francisco](mailto:ClinicalResearch%40sutterhealth.org?subject=More%20information%20on%20Adjuvant%20Non%20Small%20Lung%20Cancer%20TroFuse-019%20in%20San%20Francisco&body=Please%20be%20aware%20that%20if%20you%20reply%20with%20unencrypted%20email%2C%20this%20increases%20the%20risk%20that%20information%20could%20be%20read%20by%20an%20unauthorized%20third%20party.%20Please%20do%20not%20include%20any%20Protected%20Health%20Information%20in%20your%20email%20response.) ## Related clinical trials [View all clinical trials](https://www.sutterhealth.org/research-search-results?verticalKey=clinical_trial) - Clinical trial ### [Adjuvant Early-stage Non-small Cell Lung Cancer Beamion LUNG-3](https://www.sutterhealth.org/research/clinical-trials/adjuvant-early-stage-non-small-cell-lung-cancer-beamion-lung-3-2084403277) Beamion LUNG-3: A Randomized, Controlled, Multi-center Trial Evaluating Zongertinib as an Adjuvant Monotherapy Compared With Standard of Care in Patients With Early-stage, Resectable Non-small Cell Lung Cancer (Stage II-IIIB) Harboring Tyrosine Kinase Domain Activating HER2 Mutations **Status:** Open to Enrollment - Clinical trial ### [Adjuvant Monotherapy vs. Standard of Care Early-stage, Resectable Non-small Cell Lung Cancer](https://www.sutterhealth.org/research/clinical-trials/adjuvant-monotherapy-vs-standard-of-care-early-stage-resectable-non-small-cell-lung-cancer-2082765455) Beamion LUNG-3: A Randomized, Controlled, Multi-center Trial Evaluating Zongertinib as an Adjuvant Monotherapy Compared With Standard of Care in Patients With Early-stage, Resectable Non-small Cell Lung Cancer (Stage II-IIIB) Harboring Tyrosine Kinase Domain Activating HER2 Mutations **Status:** Coming Soon - Clinical trial ### [Adjuvant Non-Small Cell Lung Cancer A081801](https://www.sutterhealth.org/research/clinical-trials/adjuvant-non-small-cell-lung-cancer-a081801-1049141795) Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO **Status:** Open to Enrollment - Clinical trial ### [Adjuvant Non-Small-Cell Lung Cancer C5851005 PADL1NK-005](https://www.sutterhealth.org/research/clinical-trials/adjuvant-non-small-cell-lung-cancer-c5851005-padl1nk-005-2064313501) PADL1NK-005: A Randomized, Phase 3, Open-Label Study to Evaluate PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC) **Status:** Open to Enrollment - Clinical trial ### [Advanced Non-Small Cell Lung Cancer S1900K](https://www.sutterhealth.org/research/clinical-trials/interventional-lung-s1900k-lungmap-substudy-1049141939) A Randomized Phase II Study of Tepotinib With or Without Ramucirumab in Participants With MET Exon 14 Skipping Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP SUB-STUDY) **Status:** Open to Enrollment [View all clinical trials](https://www.sutterhealth.org/research-search-results?verticalKey=clinical_trial) ```json {"@context":"https://schema.org","@type":"MedicalOrganization","name":"Sutter Health","@id":"https://www.sutterhealth.org/#medicalorganization","url":"https://www.sutterhealth.org","logo":"https://www.sutterhealth.org/static/images/sutter-health-logo.svg","address":{"@type":"PostalAddress","streetAddress":"2200 River Plaza Drive","addressLocality":"Sacramento","addressRegion":"CA","postalCode":"95833","addressCountry":"US"},"areaServed":{"@type":"AdministrativeArea","name":"California"},"sameAs":["https://www.facebook.com/SutterHealth","https://www.instagram.com/sutterhealth/","https://x.com/SutterHealth","https://www.youtube.com/sutterhealth","https://www.linkedin.com/company/sutter-health","https://en.wikipedia.org/wiki/Sutter_Health"]} ``` ```json {"@context":"https://schema.org","@type":"BreadcrumbList","@id":"https://www.sutterhealth.org/research/clinical-trials/adjuvant-non-small-lung-cancer-trofuse-019-2015848648#breadcrumblist","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https://www.sutterhealth.org/"},{"@type":"ListItem","position":2,"name":"Research","item":"https://www.sutterhealth.org/research"},{"@type":"ListItem","position":3,"name":"Clinical trials","item":"https://www.sutterhealth.org/research/clinical-trials"},{"@type":"ListItem","position":4,"name":"Adjuvant Non Small Lung Cancer TroFuse-019"}]} ``` ```json {"@context":"https://schema.org","@type":"MedicalWebPage","@id":"https://www.sutterhealth.org/research/clinical-trials/adjuvant-non-small-lung-cancer-trofuse-019-2015848648#medicalwebpage","name":"Adjuvant Non Small Lung Cancer TroFuse-019","description":"A Phase 3 Randomized Open-Label Study of Adjuvant Pembrolizumab With or Without MK-2870 in Participants With Resectable Stage II to IIIB (N2) NSCLC Not Achieving pCR After Receiving Neoadjuvant Pembrolizumab With Platinum-based Doublet Chemotherapy Followed by Surgery (MK-2870-019) (TroFuse-019)","url":"https://www.sutterhealth.org/research/clinical-trials/adjuvant-non-small-lung-cancer-trofuse-019-2015848648","inLanguage":"en-US","dateModified":"2026-05-21","publisher":{"@type":"MedicalOrganization","name":"Sutter Health","@id":"https://www.sutterhealth.org/#medicalorganization","url":"https://www.sutterhealth.org"},"medicalAudience":{"@type":"MedicalAudience","audienceType":"Patient"},"mainEntity":{"@id":"https://www.sutterhealth.org/research/clinical-trials/adjuvant-non-small-lung-cancer-trofuse-019-2015848648#medicaltrial"},"breadcrumb":{"@id":"https://www.sutterhealth.org/research/clinical-trials/adjuvant-non-small-lung-cancer-trofuse-019-2015848648#breadcrumblist"},"mentions":[{"@type":"Person","name":"Alan M Kramer, M.D.","url":"https://www.sutterhealth.org/research/investigators/alan-m-kramer-md-1049681189","jobTitle":"Principal Investigator","affiliation":{"@type":"MedicalOrganization","name":"Sutter Health","@id":"https://www.sutterhealth.org/#medicalorganization","url":"https://www.sutterhealth.org"}}]} ``` ```json {"@context":"https://schema.org","@type":"MedicalTrial","@id":"https://www.sutterhealth.org/research/clinical-trials/adjuvant-non-small-lung-cancer-trofuse-019-2015848648#medicaltrial","name":"Adjuvant Non Small Lung Cancer TroFuse-019","alternateName":"A Phase 3 Randomized Open-Label Study of Adjuvant Pembrolizumab With or Without MK-2870 in Participants With Resectable Stage II to IIIB (N2) NSCLC Not Achieving pCR After Receiving Neoadjuvant Pembrolizumab With Platinum-based Doublet Chemotherapy Followed by Surgery (MK-2870-019) (TroFuse-019)","url":"https://www.sutterhealth.org/research/clinical-trials/adjuvant-non-small-lung-cancer-trofuse-019-2015848648","description":"This study will assess if adding sacituzumab tirumotecan with pembrolizumab after surgery is effective in treating NSCLC for participants not achieving pathological complete response. The primary hypothesis of this study is sacituzumab tirumotecan plus pembrolizumab is superior to pembrolizumab monotherapy with respect to disease free survival (DFS) as assessed by blinded independent central review (BICR).","identifier":"NCT06312137","code":{"@type":"MedicalCode","codeValue":"NCT06312137","codingSystem":"ClinicalTrials.gov"},"sameAs":"https://www.clinicaltrials.gov/study/NCT06312137","status":"https://schema.org/Recruiting","healthCondition":[{"@type":"MedicalCondition","name":"Lung Cancer"}],"studyLocation":[{"@type":"AdministrativeArea","name":"San Francisco"}]} ```